Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18646412 | 0.80 | KDM4E (0.45) | KDM4ELMNAGFERL3MBTL1PARP1 | |
| SCHEMBL13977598 | 0.76 | KDM4E (0.49) | KDM4ELMNAGFERL3MBTL1TDP1 | |
| SCHEMBL26328790 | 0.73 | KDM4E (0.42) | KDM4ELMNAGFERL3MBTL1PARP1 | |
| SCHEMBL5019115 | 0.72 | LMNA (0.50) | KDM4ELMNAGFERL3MBTL1PARP1 | |
| SCHEMBL13055397 | 0.72 | KDM4A (0.51) | KDM4ELMNAL3MBTL1TDP1KDM4A | |
| SCHEMBL22535987 | 0.72 | TDP1 (0.46) | KDM4ELMNAGFERL3MBTL1TDP1 | |
| SCHEMBL572016 | 0.72 | TDP1 (0.46) | KDM4ELMNAGFERL3MBTL1TDP1 | |
| SCHEMBL3180689 | 0.72 | L3MBTL1 (0.61) | L3MBTL1TDP1KDM4ANPSR1GAA | |
| SCHEMBL17107898 | 0.71 | L3MBTL1 (0.50) | KDM4ELMNAGFERL3MBTL1PARP1 | |
| SCHEMBL22535990 | 0.70 | TDP1 (0.44) | KDM4ELMNAGFERL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| EP-3973993-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | Tagworks Pharmaceuticals B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-2709666-B1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS NV (NL) | 2021-07-14 | — | — | EP | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| WO-2012156920-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KDM4E 1403/4885LMNA 4539/4885GFER 2469/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | KDM4E 1403/4885LMNA 4539/4885GFER 2469/4885 |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KDM4E 1403/4885LMNA 4539/4885GFER 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.